FGP
LGND icon

Freestone Grove Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Freestone Grove Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$562K Sell
2,817
-50
-2% -$9.89K ﹤0.01% 580
2025
Q4 		$542K Buy
+2,867
New +$551K ﹤0.01% 558

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Freestone Grove Partners's LGND Position: Q1 2026 in Review

Freestone Grove Partners reduced its Ligand Pharmaceuticals (LGND) stake by 1.7% in Q1 2026, selling an estimated $9.89K and leaving 2,817 shares worth $562K. The position accounts for ﹤0.01% of the portfolio, ranked #580.

Freestone Grove Partners first reported a position in LGND in Q4 2025 and has held it in 2 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Freestone Grove Partners held 2,817 shares of Ligand Pharmaceuticals worth $562K as of Q1 2026.
  • Freestone Grove Partners sold 50 Ligand Pharmaceuticals shares in Q1 2026, an estimated $9.89K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #580 holding.
  • Freestone Grove Partners first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.